The unit is curently working on multiple research projects in collaboration with the pharmaceutical industry as well as its investigator-initiated research projects. one of the collaborations is with the Asia Pacific Lupus Collaboration, led by Professor Eric Morand from Monash University of Melbourne, Australia. The unit also has other research collaborations including with the National Institute of Health Malaysia on Lupus research and APLAR (Asia Pacific League of Associations for Rheumatology) in the field of scleroderma and myositis.
Genarally, the unit generates an average output of about 2 to 3 publications per year in ISI peer-reviewed journals, which includes recent research on RA, SLE, Axial Spondyloarthritis, and Scleroderma.
Pharmaceutical industry-initiated clinical trials have also been conducted wtih the support of the Clinical Investigations Centre at UMMC. Currently, the Clincial trial studies involved are of Phases 2, 3 and 4. The unit is also currently int he pipeline of initiating a Phase 1 Clinical trial at UMMC.
* UM Rheumatology is actively participating pharmaceutical sponsored clinical trials in the field is Rheumatology for rheumatic diseases like RA, PSA, axial SpA, SLE, systemic sclerosis and gout.
|
1
|
iLUPUS - Identification of autoantibody-defined subgroups among the Malaysian systemic lupus erythematosus patients based on SLE- associated autoantibody profile. |
|
2
|
DOMRSF-2023-01/C4: Prevalence and Clinical Associations of Cerebral Atrophy in Patients with Systemic Lupus Erythematosus. |
|
3
|
Survival Of Systemic Sclerosis Patients with Interstitial Lung Disease in Malaysia. |
|
1
|
SENSCIS trial: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD). |
|
2
|
SENCearly Trial: A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nintedanib in patients with early diffuse cutaneous Systemic Sclerosis associated Interstitial Lung Disease (dcSSc-ILD): |
| 3 |
VITALISScE trial: A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis. |
| 4 | CONQUEST : A multicenter, double-blind, randomized, placebo-controlled, phase 2b platform clinical study to evaluate the safety and efficacy of investigational products in participants with interstitial lung disease secondary to systemic sclerosis. |
| 5 | DAISY trial : A multicenter, randomized, parallel-group, double-blind, two-arm, phase iii study to evaluate the safety and efficacy of Anifrolumab compared with placebo in male and female participants 18 to 70 years of age inclusive with systemic sclerosis. |
| 6 | CVAY736S12201 : A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of Ianalumab in participants with diffuse cutaneous systemic sclerosis. |
| 7 |
CAIN457A02001B An open-label, multicenter protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to ben-efit from continued Secukinumab treatment |
| 8 |
FINCH-4 Trial: A multicenter, double-blind, long term extension study to assess the safety and efficacy of Filgotinib in subjects with rheumatoid arthritis |
| 9 |
CONTRAST Trial: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate. |
| 10 |
JW21301: A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients. |
| 11 |
LG-GDCL010: A randomized, multi-regional, double-blind, double-dummy parallel group, placebo and allopurinol-controlled phase 3 study to assess the efficacy and safety of Tigulixostat in gout patients with hyperuricemia |
| 12 |
M 16- 011; A phase 3, randomized, double-blind, study comparing risankizumab tp placebo in subjects with active psoriatic arthiritis (PsA) who have a history of inadequate response to or intolerance to at least one disease modifying anti-rheumatic drug (DMARD) |
| 13 |
MK -6194-006: A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MK-6194 in adult participants with systemic lupus erythematosus. |
| 14 | RATIONAL trial: Prevalence study of gastrointestinal risk factors in patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis receiving treatment with non-steroidal anti-inflammatory drugs. |
| 15 |
STAR trial: A phase 4, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Guselkumab administered subcutaneously in bio-naive participants with active psoriatic arthritis axial disease. |
| 16 |
APEX Trial: A phase 3b, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of subcutaneously administered Guselkumab in improving the signs and symptoms and inhibiting radiographic progression in participants with active psoriatic arthritis. |
| 17 | CVAY736F12302: A phase 3b, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of subcutaneously administered Guselkumab in improving the signs and symptoms and inhibiting radiographic progression in participants with active psoriatic arthritis. |
Last Update: 13/11/2024